**India I Equities** 

Technology

### **Company Update**

Change in Estimates ☑ Target ☑ Reco □

24 January 2023

# **LTIMindtree**

Growth in-line, margins lower due to one-offs; maintaining a Buy

With revenue up 2.4% q/q (~1% from pass-throughs) to ~\$1,047m, LTI-Mindtree grew on par with the industry and in line with our expectations. TCV was \$1.25bn, a book-to-bill of 1.2x (Mindtree operated in the past at 1.2x). The EBIT margin was lower due to more Hi-tech furloughs, employee costs and integration costs which may not recur in Q4, leading to management guidance of a 200bp expansion in Q4. Attrition moved down further and industry tailwinds are likely to continue. Estimates are largely unchanged with a revised TP of Rs5,520 (from Rs5,630) at 26x (unchanged) FY25e.

Large deal pipeline at record high, Q3 revenues affected by furloughs. Q3 revenue was up 2.4% q/q, 13.8% y/y, largely driven by Manufacturing & resources (up 10.5% q/q) and BFSI (up 5.7% q/q). Weakness was seen in Hitech (down 4/7% q/q) due to furloughs but the company is confident of recovering in Q4. The company is seeing deferred demand in certain projects and delays in decision-making but is yet confident of growth, given its current pipeline. It is also experiencing an increase in cost take-out deals.

**EBIT** margin to expand 200-250bps in Q4. In Q3, the EBIT margin was down ~260bps q/q, 360bps y/y (on adj. for M&A cost: 100bps) to 14.9%. This was largely due to furloughs (130bps) and rises in employee costs (130bps). The latter was higher due to ESOPs to top management and increments to fresh graduates. As some of these are non-recurring, Management guided to a 200-250bp margin expansion in Q4. Utilisation incl. trainees (est.) was 81.5% and offers headroom for improvement. Headcount moved down 474 in Q3 to 86,462; attrition also moved down, to 22.3% from 24.1% in Q2. We expect net addition to turn positive given current utilisation.

**Retaining a Buy.** We expect LTIM to deliver a 13% revenue CAGR over FY23-25 and increase EBIT margins to ~18% by FY25, from 16.3% in FY23, leading to a 20% EBIT CAGR. This would result in an EPS of Rs.213 for FY25. The stock trades at FY25e PE of 20x which we find attractive; our target is based on 26x FY25e EPS (Rs5,520). **Risks**: Continued headwinds in Hi-tech; high integration costs.

Key financials (YE Mar)	FY21	FY22	FY23e	FY24e	FY25e
Sales (Rs m)	123,698	156,687	333,279	382,898	435,030
Net profit (Rs m)	19,384	22,969	44,584	53,070	62,980
EPS (Rs)	110.4	130.8	150.5	179.1	212.5
P E (x)	66.7	56.3	29.0	24.4	20.5
EV / EBITDA (x)	44.5	39.6	19.7	16.5	14.1
P/BV (x)	17.7	14.7	7.9	6.7	5.8
RoE (%)	30.5	28.5	29.1	29.8	30.2
RoCE (%)	23.8	22.3	29.6	25.0	25.5
Dividend yield (%)	0.9	1.3	1.7	1.8	2.4
Net debt / equity (x)	-0.6	-0.5	-0.5	-0.5	-0.5
Source: Company, Anand Rathi Research	Note: F	Y23 includes Mind	ltree		

Rating: Buy

Target Price: Rs.5,520 Share Price: Rs.4,361

Key data	LTI IN / LRTI.BO
52-week high / low	Rs.6,525 / 3733
Sensex / Nifty	60942 / 18119
3-m average volume	\$24.6m
Market cap	Rs.1,292bn / \$15877.1m
Shares outstanding	296m

Shareholding pattern (%)	Dec'22	Sep'22	Jun'22
Promoters	68.7	74.0	74.0
- of which, Pledged	-	-	-
Free float	31.3	26.0	26.0
- Foreign institutions	9.2	8.1	8.4
- Domestic institutions	10.5	8.1	8.1
- Public	11.6	9.7	9.5

Estimates revision (%)	FY23e	FY24e	FY25e
Sales (\$)	(0.0)	(0.5)	(1.0)
EBITDA	(1.5)	(2.2)	(1.5)
Net Profit	(0.3)	(0.8)	(1.4)



Source: Bloomberg

Mohit Jain Research Analyst

Krishna Thakker Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

# **Quick Glance - Financials and Valuations**

Revenues (US\$m)         1,670.0         2,102.6         4,122.1         4,653.9         5,21           Growth (%)         9.5         25.9         17.7         12.9         7           Net revenues (Rs m)         123,698         156,687         333,279         382,898         435,288           Employee & Direct Costs         91,617         119,763         253,282         290,728         328,328           Gross Profit         32,081         36,924         79,997         92,170         106,329           Gross Margin %         25.93         23.57         24.00         24.07         24.07           SG&A         4,830         6,339         18,355         18,878         20,20           EBITDA margins (%)         22.0         19.5         18.5         19.1         7.22         86,22           Chher income         2,743         4,667         5,780         6,993         8,355         18,78         19.1           PBT         25,881         30,975         58,757         71,132         84,232           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8 <t< th=""><th>Fig 1 – Income statement (Rs m)</th><th></th><th></th><th></th><th></th><th></th></t<>	Fig 1 – Income statement (Rs m)					
Growth (%)         9.5         25.9         17.7         12.9           Net revenues (Rs m)         123,698         156,687         333,279         382,898         435,288           Employee & Direct Costs         91,617         119,763         253,282         290,728         328,388           Gross Profit         32,081         36,924         79,997         92,170         106,32           Gross Margin %         25.93         23.57         24.00         24.07         24.07           SG&A         4,830         6,339         18,355         18,878         20,81           EBITDA         27,251         30,585         61,643         73,292         86,61           EBITDA margins (%)         22.0         19.5         18.5         19.1         19.1           - Depreciation         3,325         3,549         7,221         7,637         8,767           Other income         2,743         4,667         5,780         6,993         8,8           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26	Year-end: Mar	FY21	FY22	FY23e	FY24e	FY25e
Net revenues (Rs m)         123,698         156,687         333,279         382,898         435,           Employee & Direct Costs         91,617         119,763         253,282         290,728         328,           Gross Profit         32,081         36,924         79,997         92,170         106,           Gross Margin %         25.93         23.57         24.00         24.07         22           SG&A         4,830         6,339         18,355         18,878         20,           EBITDA         27,251         30,585         61,643         73,292         86,           EBITDA margins (%)         22.0         19.5         18.5         19.1	Revenues (US\$m)	1,670.0	2,102.6	4,122.1	4,653.9	5,287.6
Employee & Direct Costs         91,617         119,763         253,282         290,728         328, 328           Gross Profit         32,081         36,924         79,997         92,170         106, 329           Gross Margin %         25,93         23,57         24,00         24,07         24,07           SG&A         4,830         6,339         18,355         18,878         20, 32,251           EBITDA         27,251         30,585         61,643         73,292         86, 339           EBITDA margins (%)         22.0         19.5         18.5         19.1         19.1           - Depreciation         3,325         3,549         7,221         7,637         8, 38, 38, 38, 38, 38, 38, 38, 38, 38, 3	Growth (%)	9.5	25.9	17.7	12.9	13.6
Gross Profit         32,081         36,924         79,997         92,170         106,           Gross Margin %         25.93         23.57         24.00         24.07         24.07           SG&A         4,830         6,339         18,355         18,878         20,           EBITDA         27,251         30,585         61,643         73,292         86,           EBITDA margins (%)         22.0         19.5         18.5         19.1         -           - Depreciation         3,325         3,549         7,221         7,637         8,           Other income         2,743         4,667         5,780         6,993         8,           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296	Net revenues (Rs m)	123,698	156,687	333,279	382,898	435,030
Gross Margin %         25.93         23.57         24.00         24.07         2           SG&A         4,830         6,339         18,355         18,878         20,           EBITDA         27,251         30,585         61,643         73,292         86,           EBITDA margins (%)         22.0         19.5         18.5         19.1         -           - Depreciation         3,325         3,549         7,221         7,637         8,           Other income         2,743         4,667         5,780         6,993         8,           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296         296	Employee & Direct Costs	91,617	119,763	253,282	290,728	328,046
SG&A         4,830         6,339         18,355         18,878         20,           EBITDA         27,251         30,585         61,643         73,292         86,           EBITDA margins (%)         22.0         19.5         18.5         19.1         7.637         8,           - Depreciation         3,325         3,549         7,221         7,637         8,           Other income         2,743         4,667         5,780         6,993         8,           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296         296	Gross Profit	32,081	36,924	79,997	92,170	106,984
EBITDA         27,251         30,585         61,643         73,292         86,           EBITDA margins (%)         22.0         19.5         18.5         19.1         -           - Depreciation         3,325         3,549         7,221         7,637         8,           Other income         2,743         4,667         5,780         6,993         8,           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296         296	Gross Margin %	25.93	23.57	24.00	24.07	24.59
EBITDA margins (%)         22.0         19.5         18.5         19.1           - Depreciation         3,325         3,549         7,221         7,637         8,           Other income         2,743         4,667         5,780         6,993         8,           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296         296	SG&A	4,830	6,339	18,355	18,878	20,919
- Depreciation         3,325         3,549         7,221         7,637         8,           Other income         2,743         4,667         5,780         6,993         8,           Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,767         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296	EBITDA	27,251	30,585	61,643	73,292	86,065
Other income         2,743         4,667         5,780         6,993         8, Interest Exp         788         728         1,445         1,516         1, T516         2, T5	EBITDA margins (%)	22.0	19.5	18.5	19.1	19.8
Interest Exp         788         728         1,445         1,516         1,           PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         26	- Depreciation	3,325	3,549	7,221	7,637	8,267
PBT         25,881         30,975         58,757         71,132         84,           Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         296	Other income	2,743	4,667	5,780	6,993	8,432
Effective tax rate (%)         25         26         24         25           + Associates/(Minorities)         3         -17         -18         -8           Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         29	Interest Exp	788	728	1,445	1,516	1,516
+ Associates/(Minorities) 3 -17 -18 -8  Net Income 19,384 22,969 44,584 53,070 62,9  WANS 176 176 296 296 29	PBT	25,881	30,975	58,757	71,132	84,714
Net Income         19,384         22,969         44,584         53,070         62,9           WANS         176         176         296         296         2	Effective tax rate (%)	25	26	24	25	26
WANS 176 176 296 296 2	+ Associates/(Minorities)	3	-17	-18	-8	-8
	Net Income	19,384	22,969	44,584	53,070	62,980
FDEPS (Rs/share) 110.4 130.8 150.5 179.1 212	WANS	176	176	296	296	296
	FDEPS (Rs/share)	110.4	130.8	150.5	179.1	212.5

Fig 2 – Balance sheet (Rs m)					
Year-end: Mar	FY21	FY22	FY23e	FY24e	FY25e
Share capital	175	175	295	295	295
Net worth	73,034	88,146	163,359	192,547	224,038
Total debt (incl. Pref)	414	519	-	-	-
Minority interest	37	57	75	83	91
DTL/(Asset)	-511	-444	-6,322	-6,322	-6,322
Capital employed	72,974	88,278	157,112	186,308	217,807
Net tangible assets	10,078	11,359	25,750	25,622	24,881
Net Intangible assets	9,241	10,057	14,657	13,657	12,657
Goodwill	6,574	6,900	6,900	6,900	6,900
CWIP (tang. & intang.)	403	4,374	4,589	4,589	4,589
Investments (Strategic)					
Investments (Financial)	38,890	34,820	57,453	74,689	112,033
Current Assets (ex Cash)	40,339	55,761	98,705	111,232	124,045
Cash	7,594	7,773	24,327	25,035	9,448
Current Liabilities	33,571	35,866	68,369	68,516	69,846
Working capital	6,768	19,895	30,336	42,716	54,199
Capital deployed	72,974	88,278	157,112	186,308	217,807
Contingent Liabilities	3,791	3,803	-	-	-

Fig 3 – Cash Flow statement (Rs m)									
Year-end: Mar	FY21	FY22	FY23e	FY24e	FY25e				
PBT	25,881	30,975	58,757	71,132	84,714				
+ Non-cash items	1,811	3,200	7,220	7,637	8,267				
Operating profit before WC chang	27,692	34,175	65,977	78,769	92,980				
- Incr./(decr.) in WC	-2,704	9,542	19,291	12,380	11,482				
Others incuding taxes	-6,400	-8,113	-11,904	-18,054	-21,725				
Operating cash-flow	23,996	16,520	34,782	48,335	59,773				
- Capex (tangible + Intangible)	2,719	8,590	11,665	6,509	6,525				
Free cash-flow	21,277	7,930	23,117	41,826	53,247				
Acquisitions	-426	-779	-904	-	-				
- Dividend (including buyback & ta	5,319	8,749	22,292	23,882	31,490				
+ Equity raised	1	-	-	-	-				
+ Debt raised	94	105	-519	-	-				
- Fin Investments	14,611	-2,189	-17,367	17,236	37,344				
- Misc. Items (CFI + CFF)	-1,326	517	215	-	-				
Net cash-flow	2,342	179	16,554	708	-15,588				

Fig 4 – Ratio analysis					
Year end Mar	FY21	FY22	FY23e	FY24e	FY25e
P/E (x)	66.7	56.3	29.0	24.4	20.5
EV/EBITDA(x)	44.5	39.6	19.7	16.5	14.1
EV/sales (x)	9.8	7.7	3.6	3.2	2.8
P/B (x)	17.7	14.7	7.9	6.7	5.8
RoE (%)	30.5	28.5	29.1	29.8	30.2
RoCE (%) - After tax	23.8	22.3	29.6	25.0	25.5
RoIC (%) - After tax	46.6	44.3	53.5	46.5	49.9
DPS (Rs per share)	40.0	55.0	75.2	80.6	106.3
Dividend yield (%)	0.9	1.3	1.7	1.8	2.4
Dividend payout (%) - Inc. DDT	36.2	42.1	50.0	45.0	50.0
Net debt/equity (x)	-0.6	-0.5	-0.5	-0.5	-0.5
Receivables (days)	79	87	80	79	77
Payables (days)	31	23	21	20	20
CFO:PAT%	123.8	71.9	78.0	91.1	94.9
FCF:PAT% - includ M&A payou	107.6	31.1	49.8	78.8	84.5
Source: Company, Anand Rathi Research					

Fig 5 - Price movement





Fig 6 – EBITDA margin (LTIMindtree, Proforma till Q1 FY23)



# **Quarterly result**

Fig 7 - LTIMindtree quarterly result Q4FY22 Q1FY23 Q2FY23 Q3FY23 Revenue (\$ m) 954 980 1.022 1.047 2.4% 13.8% Growth Y/Y % 31% 30% 25% 19% 14% Industry Y/Y % (est.) 20% 21% 16% 13% 9% Revenue (Rs m) 68,876 71,990 76,439 82,278 86,200 4.8% 25.2% Effec. exchange rate 82.4 9.9% Net New TCV (\$ m) LTI 32 80 80 NA TCV(LTM) 128 142 221 271 NA MTCL TCV (\$ m) 358 390 570 518 NA TCV(LTM) 1,597 1,612 1,678 1,836 NA Visibility Total TCV (LTIM) 1,250 Employees (EoP) 76,159 81,719 84,030 86,936 86,462 -0.5% 13.5% Rev. prod. (\$ '000/employee) 12.4 12.1 11.8 12.0 12.1 1.0% -2.7% 80.3% 80.1% 83.0% 81.5% -90 bps 120 bps Utilisation % (LTI) 82.4% Utilisation % (MTCL) 81.5% 83.1% 81.2% 80.7% NA Attrition LTI 22.5% 24.0% 24.0% 24.1% 22.3% -180 bps -20 bps Attrition MTCL 21.9% 23.8% 24.5% 24.1% NA CoR (excl. D&A) (50,634) (52,979) (56,857) (61,912) (66,350) 7.2% 31.0% As % of revenue -74% -74% -75% -77% 172 bps -346 bps SG&A (4,464) (4,010) 29.7% (4,010) (4,693) 29.7% (5,202)As % of revenue. -6% -6% -6% -21 bps -6% -5% -116 bps 14 232 14 547 14 889 14 648 FRITDA 16 356 -10.4% 29% EBIT DA margins % 20.7% 20.2% 19.5% 19.9% 17.0% -289 bps -367 bps EBIT 12.715 12,932 13,225 14.397 12,867 -10.6% 1.2% EBIT margins % 18.5% 18.0% 17.3% 17.5% 14.9% -257 bps -353 bps Industry margins % (est.) 17.9% 17.3% 16.4% 14.6% 15.4% 78 bps -259 bps Other income (excl. forex) 579 829 966 1,413 1,028 -27.2% 77.5% 1.128 1.410 870 -136.3% Non-recurring / Forex 198 (410) -307.1% Interest expenses (378) 20.3% (315) (310)(309)(379)0.3% PBT 14.107 14.861 14,752 15,630 13,106 -16.1% -7.1% PBT margins % 20.5% 20.6% 19.3% 19.0% 15.2% -379 bps -528 bps (3,607) (3,755) (3,705) (3,740) (3,099) -17.1% -14.1% ETR % -26% -25% -25% -24% -24% 28 bps 192 bps Minority interest/Income from associates -60.0% -60.0% (5) (5) (9) (5) (2) 10,495 11,101 11,038 11,885 10,005 -4.7% Netincome -15.8% Net margins % 15.2% 15.4% 14.4% 14.4% 11.6% -284 bps -363 bps

Fig	8 –	Quart	erly	resu	lts
-----	-----	-------	------	------	-----

Industry net margins %

				9M as % of		FY23e % chg.	FY24e % chg.
Year-end: Mar (Rs m)	Q3FY23	% chg. Q/Q	% chg. Y/Y	FY23	FY23e	Y/Y	Y/Y
Sales (\$ m)	1,047	2.4	13.8	74	4,122	17.3	12.9
Sales	86,200	4.8	25.2	73	333,279	27.2	14.9
EBITDA	14,648	(10.4)	2.9	74	61,643	17.3	18.9
EBITDA margin (%)	17.0	-289bps	-367bps		18.5	-156bps	65bps
EBIT	12,867	(10.6)	1.2	74	54,422	16.9	20.6
EBIT margin (%)	14.9	-257bps	-353bps		16.3	-145bps	82bps
PBT	13,106	(16.1)	(7.1)	74	58,756	10.7	21.1
Tax	(3,099)	(17.1)	(14.1)	74	(14,154)	4.3	27.6
Tax rate (%)	(23.6)	28bps	192bps		(24.1)	147bps	-129bps
Net income	10,005	(15.8)	(4.7)	74	44,584	12.9	19.0
Source: Company, Anan	d Rathi Resea	rch					

14.3%

12.5%

37.3

11.8%

40.1

11.1%

33.8

-70 bps

-15.8%

-288 bps

-4.7%


14.0%


35.4

Source: Company, Anand Rathi Research Note: Pro forma till Q1FY23

# Continues to grow faster than industry; Q3 an aberration

LTIMindtree's Q3 FY23 \$1,047m revenue was in line with expectations, up 2.4% q/q, higher than industry growth for the ninth successive quarter and despite more-than-usual furloughs in Hi-tech. Y/y though, the company grew faster than the industry for the seventh consecutive quarter and is likely to retain this outpacing as some of the concentrated exposures to verticals are now better diversified (BFSI, Retail CPG, Hi-tech). Further, it should benefit from revenue synergises ahead, per management, \$1bn cumulatively in 4-5 years. In the past, the company has grown ~4-8% more than the industry and we expect this gap to continue.






Source: Company, Anand Rathi Research Note: Pro forma numbers used till Q4FY22


Source: Company, Anand Rathi Research Note: Pro forma numbers used till Q4FY22

LTIM registered TCV of \$1.25bn in Q3, and management said that the large deal pipeline is at an all-time high. Deals won in the quarter include one from an American multinational financial services company (expanded engagement with LTI's Temenos capabilities), one from a global airline and one from a North American specialty insurer, among others.

Management is seeing the number of cost take-out deals increasing and is seeing deferment of certain projects but not any cancelation at this time. Hence, given the deal pipeline, it expects to remain on the growth path.

On a TTM basis, revenues have grown 21%, and the company's TCV is \$1,025m. The TCV gives us some assurance into FY24 from a growth perspective. The current book-to-bill is 1.2x (similar to that of MTCL's past book-to-bill), but behind other high-growth peers such as PSYS (1.7x; four-quarter average 1.6x) and Coforge (1.4x; four-quarter average 1.3x). Management expects acceleration ahead as the current quarter took more resources and bandwidth in executing the merger.






Source: Company, Anand Rathi Research Note: LTIM Q3 TCV is only for Q3 not LTM.

# BFSI, Manufacturing lead the way for sequential growth


In Q3 for LTIM, growth in BFSI (37% of revenue) came at 6% q/q, 22% y/y. Growth in this vertical has been above 20% y/y for the last seven quarters. Management said that the BFS portion was at a \$1bn annual runrate in Q3 and that it saw significant deals, addition of logos, rate increases and growth in the large-deals pipeline.

For LTIM, Hitech, Media and Entertainment (Hi-Tech) brings 24% to overall revenue, making it the second-largest vertical for the company. This vertical declined sequentially 4.7% q/q, but was up 8.9% y/y, lower than the company level largely due to furloughs. Within Media and Entertainment, the company secured renewals in some of the large managed services deals. Management is seeing strong demand for platform services and application modernisation, leveraging cloud for OTT streaming. Ahead, it is confident of partial recovery in this vertical in Q4 and full recovery by Q1 as furloughs get over.




In Q3, the Manufacturing vertical's (18% of total revenue) performance was strong. This is the third-largest vertical for LTIM. Growth here was driven by improvement in the outsourcing pipeline and good deals, especially in the automotive sector. The resources portfolio continues to see traction in digital

transformation of core operations. Manufacturing has grown 10.5%  $\rm q/q$ , reflecting erstwhile LTI's seasonality on equipment sales (or pass-through) although it was slightly lower than in Q3 FY22.



Source: Company, Anand Rathi Research


LTIM gets 34% of revenue from the top-10 clients. In Q3 FY23, LTIM's top clients grew slower than the company. The contribution of the top-10 fell to 33.8%, from 34.3% in Q2 and 34% in Q3 FY23. The top-10 grew 0.9% q/q, 13.3% y/y. the non-top-10 grew faster, at 3.2% q/q, 14.3% y/y.



Source: Company, Anand Rathi Research


# **Headcount and Margins decline**


LTIMindtree's headcount declined by 474 in Q3 FY23, and utilisation was  $\sim$ 82% (incl. trainees). Gross utilisation was not disclosed. Hiring in the quarter was lower sequentially than the last quarter's 2,906 as the company regains focus on utilisation. However, given its current utilisation, we expect headcount addition to resume for LTIM from Q4 FY23.




Source: Company, Anand Rathi Research Note: LTIM net addition from Q1FY23

LTIM's Q3 attrition slid 180bps sequentially to 22.3%, and management suggested that attrition should moderate further. In Q3, the quarterly annualized attrition declined more than 6%, to 18%.






From an employee-productivity perspective, LTIMindtree was steady in Q3 FY23, with some benefit accrued on account of reduced headcount in the quarter. Since the company is already running at optimal utilisation and offshore levels, synergy is the only lever to improve on this metric. Therefore, we expect this number to be steady in the near term.




Source: Company, Anand Rathi Research Note: LTIM productivity from Q1FY23

Fig 22 – Utilisation can be a lever for margins




Source: Company, Anand Rathi Research Note: Offshore by effort mix, LTIM numbers from Q1FY23, utilisation (incl. trainees) estimated.


Fig 23 - Utilisation and offshore for MTCL till Q2 FY23



Source: Company, Anand Rathi Research Note: Offshore by effort mix

LTIMindtree delivered 3% y/y EBITDA growth (after adjusting for integration costs) in Q3 FY23, falling behind the industry for only the second time in ten quarters. We believe this was largely on account of one-offs during the quarter. Y/y margins were down  $\sim$ 370bps to 17%. This was largely on account of furloughs and higher employee costs. We estimate that the company can deliver EBITDA margins of  $\sim$ 20% by FY25, which may then improve further as it unveils synergies and operating leverage of larger companies. NI was down 5% y/y, lagging the industry for the first time in the last ten quarters. This was due to lower other income (down 63% y/y, including integration costs).





Source: Company, Anand Rathi Research Note: Pro forma numbers used till Q2FY23

Source: Company, Anand Rathi Research Note: Pro forma numbers used till Q2FY23

# LTIMindtree historically strong from a clientmining perspective

LTIM's active client count was 723, up four q/q, 73 y/y. Efforts in mining have been visible in the \$5m+, \$10m+, \$20m+ and \$50m+ categories. On an LTM basis, the company added 24 clients in the \$5m+ bucket, five in \$10m+, six in \$20m+ and two in \$50m+. Clients in the \$20m+ basket have recently dropped, but that's primarily to do with rapid gain in clients in Q1 FY23 and potentially reflects weakness in Retail CPG.

Fig 26 -	Fig 26 – Client profiles (LTIM from Q1FY23)											
	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q 2FY22	Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23	Q3 FY23		
\$1m+	169	165	167	169	180	187	198	337	361	374		
\$5m+	61	60	63	66	71	73	74	130	137	144		
\$10m+	32	32	35	38	43	43	44	79	77	81		
\$20m+	16	18	18	18	21	20	24	40	38	37		
\$50m+	6	5	5	6	7	8	8	10	11	11		
\$100m+	1	1	1	1	1	1	1	2	2	2		
Source: Co	mpany. Ana	nd Rathi Re	esearch									

	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23
\$1m+	127	125	120	118	120	127	136	139	145	160
\$5m+	44	43	43	44	47	50	52	56	58	61
\$10m+	23	24	21	20	25	30	33	32	35	34
\$20m+	8	8	8	7	8	8	9	14	18	16
\$50m+	1	1	1	1	1	1	1	1	1	1
\$100m+	1	1	1	1	1	1	1	1	1	1

# Conference-call highlights

- Q3 had pass-through revenues, which were similar y/y
- BFSI seeing significant deals with existing and new logos, rate increases and a growing pipeline of large deals. Management is very bullish on the BFS part here
- Health, Life-sciences and Public Services. The Health portion grew 24% y/y but was partially offset by Public Services growth. The company is seeing significant opportunities in Health and Life-sciences
- The Hi-tech vertical was affected by furloughs; expected to recover in Q4
- The Manufacturing vertical was aided by automotive deals
- Retail clients are cautious because of inflation
- TTH growth is strong here; momentum to continue except in the real estate part of this business, which has been affected by increasing rates
- Order inflows were of \$1.25bn. Management isn't seeing any program cancellation but delays in decision-making and deferment of certain projects. There is also an increase in cost take-out deals
- Cost take-out deals are larger multi-year deals. Clients are opting for cost take-out deals to keep their transformation ongoing
- Large-deal pipeline at a record high
- Minimal overlap in clients between LTI and MTCL; within BFSI, there was some overlap
- EBIT margins affected by furloughs (130bps), integration of the two companies (100bps) and more employee and operational costs (130bps). Major impact of acquisition behind
- Some acquisition and furlough costs to persist in Q4
- Employee cost up partially due to increments given to freshers
- Endeavor to operate at higher utilisation than the independent companies operated at
- Quarterly annualized attrition declined more than 6% to 18%; to continue moving down
- Billed DSO to be 50-55 in 2-3 quarters.
- The company expects \$1billion revenue from synergies in 4-5 years. Margins to see synergy benefits of 200bps-300bps in 4-5 years.

### **Business outlook**

- FY24 to return to industry-leading profitable growth
- Margins to start expanding from Q4
- ETR to be 23.6-24% in Q4, FY24 25-25.5%
- Payout of 25-30% annually.

### **Previous con calls**

### LTI

- BFS: GRC, payments and commercial banking budgets are increasing for LTI's clients. BFSI: not seeing any change in demand here, continues to be the growth driver
- Manufacturing: seeing some caution here, clients are reducing spends on discretionary programs
- E&U demand environment strong
- Hi-tech 20% y/y growth to continue (outlook unchanged, seeing good growth here, good pipeline and large deals). Hi-tech vertical declines as a large engagement moved offshore.
- Europe seeing strong demand in Cloud, ERP and Data.
- Won four large deals of TCV \$80m+, three of these are with existing clients, one with a global Fortune 500 (hi-tech company). These deals were spread across Insurance, Hi-tech and Manufacturing. the deal pipeline is \$2bn+ and has a good mix of growth and efficiency deals. Most large deals are outsourcing deals. The company is not seeing any delays in ramp-ups
- Decision time is slower than during the pandemic period but is still faster than pre pandemic times. Clients are looking to spread investments over a longer period, in particular, manufacturing clients.
- LTI and Mindtree are working together on 80+ pursuits
- Of the 22 Logos added, the BFS vertical added the most.
- The EBIT margin was 16.1%, increase in employee costs and modest utilisation were offset by currency benefits and number of working days
- Hired 1600 freshers in Q2, 1,000 in Q1 and on track to hire 6,500 for FY23.
- Attrition to moderate in H2, although niche skills attrition will not moderate as much
- Integration cost for LTIMindtree might come in Q3 and Q4 FY23.

### **Business outlook**

- Q3 performance to be as strong as or better than in Q2, and FY23 revenue growth to be in the leaders' quadrant growth
- FY23 PAT margin to be 14-15%.

## **Mindtree**

- Better pricing for niche skills was a key revenue-growth driver.
- Revenue: Q3 is a seasonally weak quarter and the company is seeing delays in program decisions across sectors. Therefore, usual seasonality will play out.
- Manufacturing: Management is seeing many DT opportunities and is bullish on this sector.
- TTH: diversification strategy delivering good results

- Healthcare: This vertical has 20 clients now and is scaling up fast.
- RCG: Muted growth due to cross-currency, and ramp-downs previously called out.
- Europe: Not seeing deals canceled but caution in decision-making. Manufacturing, RCG and Logistics seeing some delays in decision-making
- Deal wins reflect more managed-services deals and these are longer-term deals. TCV composition is a good mix of cost-optimisation and revenue-maximisation deals. Last few quarters closed multi-year opportunities.
- Delivered 21% EBITDA margin despite full wage-hike cycle in Q2
- The EBITDA margin had a 240bp impact from wage hikes, offset by the absence of one-off expense (110bps), currency benefit (50bps) and operationally efficiency (70bps)
- Facility expense and Travel expense to move up but not to be at prepandemic levels.
- Utilisation in the short run to remain in the 80-82% range
- Attrition to further trend down.

### **Business outlook**

- Industry-leading growth in FY23
- Sustain 20%+ margins.

# **Factsheet**

Fig 29 - Revenue-split, by industry (%)

Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
32.8	32.7	36.1	36.2	37.4
13.3	13.4	NA	NA	NA
10.0	10.3	15.7	15.4	15.2
17.0	16.8	16.3	16.2	17.5
11.8	11.7	25.4	25.3	23.6
8.8	8.8	6.6	6.8	6.3
6.4	6.3	NA	NA	NA
	32.8 13.3 10.0 17.0 11.8 8.8	32.8 32.7 13.3 13.4 10.0 10.3 17.0 16.8 11.8 11.7 8.8 8.8	32.8 32.7 36.1 13.3 13.4 NA 10.0 10.3 15.7 17.0 16.8 16.3 11.8 11.7 25.4 8.8 8.8 6.6	32.8     32.7     36.1     36.2       13.3     13.4     NA     NA       10.0     10.3     15.7     15.4       17.0     16.8     16.3     16.2       11.8     11.7     25.4     25.3       8.8     8.8     6.6     6.8

# Fig 30 – Revenue split by service line (%)

	Q4FY22	Q1FY23	Q2FY23	Q3FY23
33.5	33.0	37.1	36.5	NA
31.4	30.8	26.6	26.3	NA
9.3	9.7	6.2	6.2	NA
13.2	13.7	15.5	15.9	NA
12.7	12.8	14.6	15.2	NA
	31.4 9.3 13.2 12.7	31.4 30.8 9.3 9.7 13.2 13.7 12.7 12.8	31.4 30.8 26.6 9.3 9.7 6.2 13.2 13.7 15.5 12.7 12.8 14.6	31.4     30.8     26.6     26.3       9.3     9.7     6.2     6.2       13.2     13.7     15.5     15.9

Source: Company, Anand Rathi Research Note: Q3FY22 and Q4FY22 are LTI numbers. Q1FY23 and Q2FY23 are LTIM Pro forma numbers.

# Fig 31 - Revenue-split, by region (%)

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
North America	66.0	65.6	71.7	72.9	72.3
Europe (includes UK)	15.8	16.2	15.3	14.6	14.9
India	9.6	9.9	NA	NA	NA
RoW	8.6	8.3	13.0	12.5	12.8
Source: Company Anand Rathi Resea	rch Note: O3EV22 and O4	1FV22 are I TI n	umhers		

# Fig 32 – Revenue-split by delivery type and billing (%)

_					
	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
On-site	16.0	15.4	14.7	14.7	14.9
Offshore	84.0	84.6	85.3	85.3	85.1
Source: Company Anand Pathi Pasa	arch Note: O3EV22 and O4E	V22 ara I TI nur	nhare		

# Fig 33 - Client profiles (LTM)

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
Client concentration %					
Top 5	28.3	28.2	26.8	26.7	26.3
Top 10	40.4	40.4	34.5	34.3	33.8
Top 20	55.5	55.8	45.5	45.1	45.3
Growth rates Q/Q%					
Top 5	9	3	NA	4	1
Top 10	8	3	NA	4	1
Top 20	10	4	NA	3	3
Active clients	476	486	708	719	723

Fig 34 - Client profiles (LTM) - LTI

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
\$1m+	187	198	337	361	374
\$5m+	73	74	130	137	144
\$10m+	43	44	79	77	81
\$20m+	20	24	40	38	37
\$50m+	8	8	10	11	11
\$100m+	1	1	2	2	2
Client additions (LTM)					
\$1m+	22	31	54	60	58
\$5m+	13	11	21	20	24
\$10m+	11	9	13	3	5
\$20m+	2	6	14	8	6
\$50m+	3	3	2	2	2
\$100m+	0	0	0	0	0
Source: Company, Anand Rathi Research Note:	Q3FY22 and Q4F	Y22 are LTI nur	nbers		

Fig 35 – Employee movement

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
Number of employees	44,200	46,648	84,030	86,936	86,462
Net addition, quarterly	1,818	2,448	4,436	2,906	-474
Attrition % (LTI)	22.5	24.0	24.0	24.1	22.3
Attrition % (MTCL)	21.9	23.8	24.5	24.1	NA
Utilisation % (cum trainees, LTI)	80.3	80.1	83.0	82.4	81.5
Utilisation % (cum trainees, MTCL)	81.5	83.1	81.2	80.7	NA

Fig 36 – Key vertical, horizontal and geographic growth

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
Top verticals growth (Y/Y)					
BFS	39%	36%	27%	23%	22%
Insurance	15%	18%			
CPG/Retail	19%	22%	30%	12%	11%
Manufacturing	31%	27%	18%	11%	9%
Hi-tech	41%	24%	28%	21%	9%
Top horizontals growth (Y/Y)					
ADM	29%	26%	28%	15%	NA
Enterprise Solutions	29%	22%	17%	13%	NA
Enterprise Integration & Mobility	37%	51%	48%	35%	NA
IMS	19%	16%	15%	18%	NA
Analytics, Al & Cognitive	38%	47%	41%	39%	NA
Key regional growth, %, Y/Y				_	
North America	26%	26%	27%	25%	20%
Europe (includes UK)	27%	25%	16%	-1%	0%
India	44%	42%	NA	NA	NA
ROW	50%	26%	28%	16%	3%
Source: Company, Anand Rathi Research N	lote: Q3FY22 and Q4F	Y22 are LTI nui	mbers		

# **Valuations**

The stock trades at P/E of 20x FY25e, attractive given the strong pipeline and growth expected over FY23-FY25. We have not accounted for net synergies till FY25 as the management's current focus is on integration and on returning to a high-growth zone.

Both companies in the past have delivered results in the top quadrant and strong results are expected over the next two years. The stock has fallen  $\sim$ 27% in the past 12 months and is flattish (-3%) in the last six months, this is not in line with the sector which has fallen 17% in the last twelve months and is up 7% in the last six months. We, however, believe that LTIMindtree management's performance and track record in the last few years reduces some of the risks related to integration.

We project a 13% revenue CAGR over FY23-FY25. The EBIT margin was 17.8% (pro-forma) in FY22, and we project it will slip to 16.3% in FY23 on merger-related costs before returning to 17.9% by FY25. LITMindtree is expected to clock a 20% EBIT CAGR over FY23-FY25.

LTIMindtree's net cash of Rs80,406m (\$976m) at end-Q3 FY23 allows it enough headroom to re-invest in the business. Still, we don't expect any major M&A in the next 12 months, and haven't built them into our estimates. Our new target is Rs5,520 (previously Rs5,630) at 26x FY25e; we retain our Buy recommendation. No meaningful change to our estimates.

From a valuation standpoint, LTIMindtree now trades at a ~20% higher multiple than pre-pandemic averages. This, in our opinion, will hold as the company size and performance have since improved. Also, there is this aspiration of operating at a slightly higher margin range than in the past. Besides, if synergies pan out, the combined entity with newer service lines could sustain higher growth for longer or may deliver higher margins ahead.

Fig 37 - Change in estimates

(Rs m)		FY23			FY24		FY25		
	New	Old	% Change	New	Old	% Change	New	Old	% Change
Revenue (\$ m)	4,122	4,124	(0.0)	4,654	4,678	(0.5)	5,288	5,339	(1.0)
Revenues	333,279	332,952	0.1	382,898	384,106	(0.3)	435,030	438,323	(0.8)
EBITDA	61,643	62,609	(1.5)	73,292	74,924	(2.2)	86,065	87,336	(1.5)
EBITDA margins %	18.5%	18.8%	-31 bps	19.1%	19.5%	-36 bps	19.8%	19.9%	-14 bps
EBIT	54,422	54,950	(1.0)	65,655	66,355	(1.1)	77,798	78,061	(0.3)
EBIT margins %	16.3%	16.5%	-17 bps	17.1%	17.3%	-13 bps	17.9%	17.8%	7 bps
PBT	58,756	59,733	(1.6)	71,132	72,441	(1.8)	84,714	86,480	(2.0)
Net profit	44,584	44,696	(0.3)	53,070	53,504	(0.8)	62,980	63,873	(1.4)





Source: Bloomberg, Anand Rathi Research

# Risk

■ Continued headwinds in Hi-tech

### **Appendix**

#### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 23 January 2023)



#### **Anand Rathi Ratings Definitions**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps ( <us\$1bn)< td=""><td>&gt;25%</td><td>5-25%</td><td>&lt;5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd. (MCX-SX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

### Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer Marco Polo Securities Inc. Transactions in securities discussed in this research report should be effected through Marco Polo Securities Inc.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2023. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.